Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: Parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice

Paediatric Anaesthesia

Volumn 21, Issue 3, 2011, Pages 291-301

  Johnson, Trevor N ^a   Rostami Hodjegan, Amin ^a,b  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

drug drug interactions; pediatrics; physiologically based pharmacokinetic models; Simcyp ADME Simulator

Indexed keywords

ANESTHETIC AGENT; CAFFEINE; CLARITHROMYCIN; FLUCONAZOLE; IBUPROFEN; ITRACONAZOLE; MIDAZOLAM; OPIATE; RIFAMPICIN; SEDATIVE AGENT; THEOPHYLLINE; ZOLPIDEM;

ARTICLE; BIOCHEMISTRY; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; CLINICAL STUDY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; PEDIATRIC ANESTHESIA; PRIORITY JOURNAL; SIMULATION;

ALGORITHMS; ARYL HYDROCARBON HYDROXYLASES; BRAIN; CHILD; COMPUTER SIMULATION; CRITICAL ILLNESS; DRUG DESIGN; DRUG INTERACTIONS; FEMALE; FORECASTING; HUMANS; INFANT; INFANT, NEWBORN; MALE; MODELS, STATISTICAL; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; TISSUE DISTRIBUTION;

EID: 79951615778     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2010.03323.x     Document Type: Article

References (58)

1. Marshall JD, Kearns GL,. Developmental pharmacodynamics of cyclospori (Pubitemid 29350447)
2. Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000; 68: 541-555.
3. Johnson TN,. The problems in scaling adult drug doses to children. Arch Dis Child 2008; 93: 207-211. (Pubitemid 352025489)
4. Bjorkman S,. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: Theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005; 59: 691-704. (Pubitemid 40835503)
5. Edginton AN, Schmitt W, Willmann S,. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 2006; 45: 1013-1034. (Pubitemid 44436004)
6. Ginsberg G, Hattis D, Russ A, et al. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: Implications for assessing children's risks from environmental agents. J Toxicol Environ Health 2004; 67: 297-329. (Pubitemid 38200033)
7. Gentry PR, Covington TR, Clewell HJ III,. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol 2003; 38: 1-16. (Pubitemid 36873799)
8. Pelekis M, Gephart LA, Lerman SE,. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. Regul Toxicol Pharmacol 2001; 33: 12-20. (Pubitemid 32242943)
9. Price K, Haddad S, Krishnan K,. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J Toxicol Environ Health 2003; 66: 417-433. (Pubitemid 36269795)
10. Hoppu K,. Can we get the necessary clinical trials in children and avoid the unnecessary ones? Eur J Clin Pharmacol 2009; 65: 747-748.
11. Jamei M, Dickinson GL, Rostami-Hodjegan A,. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24: 53-75.
12. Johnson TN, Boussery K, Rowland-Yeo K, et al. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 2010; 49: 189-206.
13. Johnson TN, Rostami-Hodjegan A, Tucker GT,. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45: 931-956. (Pubitemid 44299829)
14. Johnson TN, Tucker GT, Tanner MS, et al. Changes in liver volume from birth to adulthood: A meta-analysis. Liver Transpl 2005; 11: 1481-1493. (Pubitemid 43072624)
15. Howgate EM, Rowland YeoK, Proctor NJ, et al. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 2006; 36: 473-497. (Pubitemid 43890728)
16. Croom EL, Stevens JC, Hines RN, et al. Human hepatic CYP2D6 developmental expression: The impact of age and genotype. Biochem Pharmacol 2009; 78: 184-190.
17. Stevens JC, Marsh SA, Zaya MJ, et al. Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 2008; 36: 1587-1593.
18. Miyagi SJ, Collier AC,. Pediatric development of glucuronidation: The ontogeny of hepatic UGT1A4. Drug Metab Dispos 2007; 35: 1587-1592. (Pubitemid 47296052)
19. Zaya MJ, Hines RN, Stevens JC,. Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos 2006; 34: 2097-2101. (Pubitemid 44837771)
20. Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625-634. (Pubitemid 27308642)
21. Stevens JC, Hines RN, Gu C, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003; 307: 573-582. (Pubitemid 37310671)
22. Chen H, Fantel AG, Juchau MR,. Catalysis of the 4-hydroxylation of retinoic acids by CYP3A7 in human fetal hepatic tissues. Drug Metab Dispos 2000; 28: 1051-1057. (Pubitemid 30660359)
23. Lee AJ, Conney AH, Zhu BT,. Human cytochrome p450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol. Cancer Res 2003; 63: 6532-6536. (Pubitemid 37255207)
24. Barter ZE, Bayliss MK, Beaune PH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8: 33-45. (Pubitemid 46043890)
25. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: A quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24: 67-76.
26. Poulin P, Theil FP,. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 2002; 91: 129-156. (Pubitemid 34074473)
27. Rodgers T, Rowland M,. Mechanistic approaches to volume of distribution predictions: Understanding the processes. Pharm Res 2007; 24: 918-933. (Pubitemid 46675393)
28. Berry LM, Roberts J, Be X, et al. Prediction of v(ss) from in vitro tissue-binding studies. Drug Metab Dispos 2010; 38: 115-121.
29. White DR, Widdowson EM, Woodard HQ, et al. The composition of body tissues (ii). Fetus to young adult. Br J Radiol 1991; 64: 149-159.
30. Woodard HQ, White DR,. The composition of body tissues. Br J Radiol 1986; 59: 1209-1218. (Pubitemid 17223252)
31. Linderkamp O, Versmold HT, Riegel KP, et al. Estimation and prediction of blood volume in infants and children. Eur J Pediatr 1977; 125: 227-234. (Pubitemid 8164670)
32. Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33: 469-503. (Pubitemid 37268185)
33. El-Husseini A, El-Basuony F, Mahmoud I, et al. Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome. Eur J Clin Pharmacol 2006; 62: 3-8. (Pubitemid 43106309)
34. Gilbert RD, Kahn D, Cassidy M,. Interaction between clonidine and cyclosporine A. Nephron 1995; 71: 105.
35. Rostami-Hodjegan A, Tucker GT,. In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions. Drug Discov Today 2004; 1: 441-448. (Pubitemid 40186348)
36. Rowland Yeo K, Jamei M, Yang J, et al. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 2010; 39: 298-309.
37. Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol 1989; 37: 267-272. (Pubitemid 19242733)
38. Brown RD, Wilson JT, Kearns GL, et al. Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children. J Clin Pharmacol 1992; 32: 231-241.
39. Blumer JL, Reed MD, Steinberg F, et al. Potential pharmacokinetic basis for zolpidem dosing in children with sleep difficulties. Clin Pharmacol Ther 2008; 83: 551-558. (Pubitemid 351417057)
40. Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46: 2554-2563. (Pubitemid 34793463)
41. Kumar L, Garg SK, Singh S, et al. Theophylline pharmacokinetics in well-nourished and malnourished asthmatic children. Int J Clin Pharmacol Ther Toxicol 1989; 27: 588-592. (Pubitemid 20053060)
42. Akinyinka OO, Sowunmi A, Honeywell R, et al. The pharmacokinetics of caffeine in nigerian children suffering from malaria and kwashiorkor. Eur J Clin Pharmacol 2000; 56: 153-158. (Pubitemid 30341390)
43. Jamei M, Turner D, Yang J, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009; 11: 225-237.
44. Mathews HM, Carson IW, Lyons SM, et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth 1988; 61: 302-307.
45. Koska AJ, Romagnoli A, Kramer WG,. Effect of cardiopulmonary bypass on fentanyl distribution and elimination. Clin Pharmacol Ther 1981; 29: 100-105. (Pubitemid 11156056)
46. Mitchell IM, Pollock JC, Jamieson MP,. The effects of congenital heart disease and cardiac surgery on liver blood flow in children. Perfusion 1995; 10: 210-218.
47. Shedlofsky SI, Israel BC, Tosheva R, et al. Endotoxin depresses hepatic cytochrome p450-mediated drug metabolism in women. Br J Clin Pharmacol 1997; 43: 627-632. (Pubitemid 27283572)
48. Carcillo JA, Doughty L, Kofos D, et al. Cytochrome p450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003; 29: 980-984. (Pubitemid 36783172)
49. Chiron C, Raynaud C, Maziere B, et al. Changes in regional cerebral blood flow during brain maturation in children and adolescents. J Nucl Med 1992; 33: 696-703.
50. Epstein HT,. Stages of increased cerebral blood flow accompany stages of rapid brain growth. Brain Dev 1999; 21: 535-539. (Pubitemid 29528317)
51. Takahashi T, Shirane R, Sato S, et al. Developmental changes of cerebral blood flow and oxygen metabolism in children. Am J Neuroradiol 1999; 20: 917-922. (Pubitemid 29536271)
52. Wintermark M, Lepori D, Cotting J, et al. Brain perfusion in children: Evolution with age assessed by quantitative perfusion computed tomography. Pediatrics 2004; 113: 1642-1652. (Pubitemid 38697970)
53. Bengtsson J, Ederoth P, Ley D, et al. The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood-brain barrier in sheep. Br J Pharmacol 2009; 157: 1085-1096.
54. Bengtsson J, Developmental Aspects of Drug Transport across the Blood-Brain Barrier. Department of Pharmaceutical Sciences. Uppsala: Uppsala University, 2009, Doctor of Philosophy in Pharmacy, pp 60.
55. European Commission regulation (EC) No 1901 /2006 (Paediatric regulation) of the European Parliament, 2006. Available at:. Accessed 30 April, 2010.
56. U.S. Congress. Best pharmaceuticals for children act: Pub L107-109, 2002, 107th congress.
57. Manolis E, Pons G,. Proposals for model-based pediatric medicinal development within the current european union regulatory framework. Br J Clin Pharmacol 2009; 68: 493-501.
58. Laer S, Barrett JS, Meibohm B,. The in silico child: Using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol 2009; 49: 889-904.